Regeneron, Eylea now 7 for 7 in beating Wall Street forecasts
Regeneron Pharmaceuticals ( $REGN ) is like a...
Read more
Read more
Archive for the 'street' tag
Feds nail key player in counterfeit Avastin probe
For more than a year, U.S. authorities have been...
Read more
Read more
State AGs amp up legal attacks on Big Pharma
Maverick states could cost Big Pharma big money....
Read more
Read more
Thanks to Lexapro generics, Forest swings to loss on 32% drop in yearly sales
No one expected Forest Laboratories to post...
Read more
Read more
Biogen MS pill soars onstage with impressive first-week script numbers
Biogen Idec's ( $BIIB ) new? multiple...
Read more
Read more
Vivus revs up new Qsymia sales plan after FDA removes a roadblock
Vivus' weight-loss drug Qsymia–courtesy...
Read more
Read more
OxyContin patent expires Tuesday but FDA under pressure to stall generics
Purdue 's original patent on the superpotent...
Read more
Read more
Big Pharma shows its claws with new compensation policies
The FDA has been talking about holding pharma...
Read more
Read more
Sanofi plots new production in China, Vietnam to fuel Asian growth
Sanofi CEO Christopher Viehbacher Sanofi CEO...
Read more
Read more
FDA saw early reports of severe Omontys reactions: WSJ
The anemia drug Omontys triggered serious...
Read more
Read more
Drugstores push for access to secret PBM pricing-and-reimbursement info
Transparency may be a trendy topic in pharma...
Read more
Read more
BD jumps into sterile injectables market, as Mylan, Teva expand
The generic sterile injectables business is...
Read more
Read more
Justices weigh arguments in generic-liability case
How is a generic drug 's label different from...
Read more
Read more
Apotex, Waxman take sides against pharma in Supreme Court generics cases
The Supreme Court is hopping with pharma news...
Read more
Read more
Ex-J&J chief’s 2012 pay outclasses Gorsky’s by almost 3-to-1
The question isn't why Johnson & Johnson...
Read more
Read more
FTC issues social-media ad rules. Will FDA finally be next?
Tired of sifting through FDA warning letters for...
Read more
Read more
Sales reps, don your badges. We’ll be watching you
Pharma reps have been known to chafe at...
Read more
Read more
Generics bite primary-care sales, but specialty drugs soar 18.4%
Suffering Big Pharma well knows that primary-care...
Read more
Read more
Bristol-Myers might just make a big deal, WSJ says
Elliott Sigal, BMS' R&D...
Read more
Read more
With Qsymia sales sputtering, Vivus shares take a dive
The advent of new obesity drugs was supposed to...
Read more
Read more
Vasella’s $78M non-compete deal sets off Swiss firestorm
The news of Daniel Vasella's $78 million...
Read more
Read more
Teva’s at-risk Protonix launch could cost $2B-plus
Pfizer is going after Teva for lost profits and...
Read more
Read more
FDA returns to Hospira plant for crucial re-inspection
CEO F. Michael Ball The days of reckoning are...
Read more
Read more
Brazilian prize, Ache, said to be evaluating possible sale
With Western drugmakers sniffing around emerging...
Read more
Read more
Court spoons out good news for Merck investors
After having to swallow a pretty bitter pill last...
Read more
Read more